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The study of how cells control the transcription of genes is
termed epigenetics. Epigenetics refers to heritable modifi-
cations in gene activities that do not involve changes in the
DNA sequence. Epigenetic processes affect gene regulation
and expression by changing the structure and conformation
of DNA within chromatin which in turn can alter the ability
of a gene to interact with transcription factors. Arguably the
most widely studied area of epigenetics is gene methyla-
tion. The next most studied is histone modification—
through affects on acetylation, methylation, phosphoryla-
tion, ubiquination and sumoylation. Of these histone
modifications, acetylation status seems to be the most
critical modification that dictates function. This acetylation
status of the histone is determined by relative activity of
two opposing enzyme families—the histone acetyltrans-
ferases (HATs) and the histone deacetylases (HDAC).
HDACs are classified by their homology to yeast HDACs.
18 are known, of which the eleven zinc-dependent metal-
loproteinases belong to class I, II, and IV. HDACs, usually in
conjunction with other co-repressor enzymes, deacetylate
lysinemoietiesinthetailsofhistones.Thealteredelectrostatic
charge leads to a relatively closed chromatin conformation
and relatively repressed transcription.
As will be detailed in this series of manuscripts, the
activity of the various members of these HDAC families
can be inhibited by histone deacetylase inhibitors (HDACi).
Before one considers the different types of HDACi, it is
critical to recognize that these HDACi have targets well
beyond nuclear histones—so called ‘non-histone targets’.
The recognition of this has led to a re-consideration of the
terminology of these compounds. Consequently, they have
been variably titled lysine-protein deacetylase inhibitors or
more simply—deacetylase inhibitors (DACi). Such non-
histone targets include p53, bcr-abl, HSP90, NFkB, HIF,
bcl-6, STATs and other transcription factors/complexes, and
the list goes on. Such targets will be discussed in depth in
the various manuscripts to follow.
Through their histone affects, DACi are generally
considered to be activators of transcription. However, gene
expression profiling shows that as many genes may be
repressed as upregulated after exposure to an histone DACi.
This is a consequence of the direct and indirect effects of
these drugs on other transcriptional regulators and cell
signaling pathways. Taken together, such targeting directly
on histones, transcription factors/complexes and non-
histone targets, gives these drugs huge potential to be
effective in a wide-range of cancers; there is also potential
for substantial short- and long-term toxicities.
DAC inhibitors share a common pharmacophore con-
taining a cap, connecting unit, linker and importantly a zinc
binding group that chelates the cations (typically zinc) in
the catalytic domain of the target HDAC and are currently
classified according to their chemical structure and have
variable ability to inhibit the deacetylase activity of specific
HDACs as will be detailed throughout the various reviews.
Indeed, not all DACi are the same! There are substantial
differences between the various DACi drugs based not only
on the targets for hyperacetylation (i.e. the different classes
of HDACs targeted – pan-DACi vs. isotype specific DACi)
but also the capacity to hyperacetylate lysine residues on
histones and non-histone target, as well as their individual
pharmacokinetic properties (oral vs. intravenous; level of
hyperacetylation; duration of hyperacetylation). For exam-
ple, it remains unclear whether tumor histone acetylation
correlates with clinical responses, or whether pan-DACi
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isotype-selective HDAC’s targeting class I alone. More-
over, as the functional profiles of various DACi vary
substantially, there is the prospect of matching them to
tumors with particular genetic profiles to improve clinical
responses.
Through these affects on histones and non-histone
protein targets the HDACi have a number of effects on
cells. These downstream effects include cytokine signaling,
cell cycle (and effects on p53), transcription factor
complexes and very importantly, apoptosis. The latter can
be induced by both the direct and indirect pathways with
key interactions with the ubiquitin, proteasome, aggresome
and NFkB systems. It is important to recognize that the
anti-tumor effect involves targeting not only the tumor cell
itself (including the putative cancer stem cell) but also the
tumor microenvironment and patient’s immune response to
the tumor.
To date, most clinical studies have used single-agent
DACi. Vorinostat and romidepsin have already been
approved by the FDA for the treatment of relapsed and
refractory cutaneous T cell lymphoma (CTCL). In this
Edition the reader will discover the various other haemato-
logical malignancies where DACi have activity—Hodgkin
lymphoma, peripheral T cell lymphoma (PTCL), B cell non
Hodgkin lymphoma, myeloma and myeloid malignancies.
Moreover, the potential synergy of DAC inhibition in
combination with many chemotherapeutic and biologically
active anti-cancer compounds in pre-clinical studies, sug-
gests combination strategies should be a major focus in
future studies. Diseases such as PTCL and CTCL currently
have a high relapse rate after standard chemotherapy and
one can envisage HDACi being incorporated in front-line
studies in such diseases. Although most patients with HL
are cured with up-front chemo-radiotherapy, there still is an
unmet clinical need for patients who relapse following
autologous stem cell transplant, and older, relapsed, patients
who are not transplantation candidates. Given the CT and
PET responses seen with MGCD0103 and panobinostat, it
seems likely Phase II and then Phase III combination
studies will follow in patients with poor prognosis disease
in the up-front setting or as maintenance.
With respect to myeloid diseases, early data indicates
clinical activity and whether specific molecularly-defined
subgroups can predict for response or resistance needs to be
a focus of future studies. Combination strategies with
chemotherapy and demethylating agents are underway but
only large Phase III studies will determine efficacy.
Moreover, study design will need to be such that these
drugs can be tested in older frailer patients to improve
survival as well as examining the possibility of HDACi
improving remission- and cure-rates when combined with
aggressive chemotherapy in younger patients—perhaps
through its potential effects on tumor stem cells. Earlier
studies in myeloma highlight the potential for rationally-
designed combinations such as DACi-proteasome-inhibitor
combinations.
Although no major long-term toxicities have been
recognized with the HDACi, one needs to recognize that
there are very few patients to date who have been treated
continuously for prolonged periods of time. Long-term
effects will need monitoring with a focus on lymphocyte,
hematopoietic, hormonal function and virus reactivation.
Finally, we need to be mindful that there is still much to
be learned about the targets of these agents that lead to
responses. Although biomarkers such as histone acetylation
have some value in correlating dose to level and duration of
hyperacetylation, it does not routinely predict for response.
Indeed, it remains unclear as to whether the intensity or
duration of acetylation is key to tumor response or whether
off target effects such as non-histone targets are more
important. Consequently, it is critical that extensive
biomarker studies continue to be incorporated into all early
phase clinical trials with these agents.
Responses observed to single agent HDACi’sh a v e
predominantly been in advanced haematological malignan-
cies, with few seen in solid tumors thus far. In this series of
manuscripts we review the current state of understanding
with an emphasis on those DACi in clinical development,
and the influence of the DACi on haematological malig-
nancies in particular.
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